A Study Designed to Compare the Tolerability of an Increased Dose of Enteric-coated Mycophenolate Acid (MPA) in Renal Transplant Patients Whose Dose of Mycophenolate Mofetil (MMF) Was Reduced Due to Gastrointestinal Symptoms
Public ClinicalTrials.gov record NCT00658333. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double Blind, Double Dummy Controlled Study to Assess the Tolerability of an Increased Dose of Enteric Coated MPA After Conversion From MMF in Renal Transplant Recipients Who Required MMF Dose Reductions Due to Gastrointestinal Symptoms
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
To determine if conversion to enteric coated MPA allows an escalated dose of mycophenolic acid (MPA) to be tolerated in patients experiencing gastrointestinal (GI) symptoms
Study identification
- NCT ID
- NCT00658333
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 30 participants
Conditions and interventions
Conditions
Interventions
- Enteric-coated Mycophenolate Acid (EC-MPA) Drug
- Mycophenolate Mofetil (MMF) Drug
- Placebo MMF Drug
- Placebo EC-MPA Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 2008 (Type not available)
- Primary completion
- Mar 2009 (Actual)
- Completion
- Mar 2009 (Actual)
- Last update posted
- Aug 7, 2012
2008 – 2009
United States locations
- U.S. sites
- 37
- U.S. states
- 22
- U.S. cities
- 31
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Novartis | Phoenix | Arizona | 85012 | — |
| Novartis | Los Angeles | California | 90033 | — |
| Novartis | Los Angeles | California | 90057 | — |
| Novartis | Los Angeles | California | 90095 | — |
| Novartis | Orange | California | 92868 | — |
| Novartis | San Diego | California | 92123 | — |
| Novartis | San Francisco | California | 94143 | — |
| Novartis | Aurora | Colorado | 80010 | — |
| Novartis | Washington D.C. | District of Columbia | 20007 | — |
| Novartis | Orlando | Florida | 32804 | — |
| Novartis | New Orleans | Louisiana | 70121 | — |
| Novartis | Portland | Maine | 04102 | — |
| Novartis | Baltimore | Maryland | 21201 | — |
| Novartis | Boston | Massachusetts | 02114 | — |
| Novartis | Boston | Massachusetts | 02215 | — |
| Novartis | Springfield | Massachusetts | 01107 | — |
| Novarits | Detroit | Michigan | 48236 | — |
| Novartis | New York | New York | 10029 | — |
| Novartis | New York | New York | 10032 | — |
| Novartis | New York | New York | 10065 | — |
| Novartis | Charlotte | North Carolina | 28207 | — |
| Novartis | Durham | North Carolina | 27710 | — |
| Novartis | Greenville | North Carolina | 27834 | — |
| Novartis | Winston-Salem | North Carolina | 27103 | — |
| Novarits | Fargo | North Dakota | 58123 | — |
| Novartis | Cleveland | Ohio | 44106 | — |
| Novartis | Portland | Oregon | 97210 | — |
| Novartis | Portland | Oregon | 97239 | — |
| Novartis | Philadelphia | Pennsylvania | 19140 | — |
| Novartis | Providence | Rhode Island | 02903 | — |
| Novartis | Nashville | Tennessee | 37232 | — |
| Novartis | Dallas | Texas | 75230 | — |
| Novartis | Houston | Texas | 77054 | — |
| Novartis | Temple | Texas | 76508 | — |
| Novartis | Murray | Utah | 84107 | — |
| Novartis | Burlington | Vermont | 05401 | — |
| Novartis | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00658333, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 7, 2012 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00658333 live on ClinicalTrials.gov.